Srini V Kaveri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2795730/publications.pdf

Version: 2024-02-01

42 papers

2,229 citations

218677 26 h-index 265206 42 g-index

42 all docs 42 docs citations

times ranked

42

2370 citing authors

#	Article	IF	CITATIONS
1	Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood, 2003, 101, 758-765.	1.4	280
2	IVIG-mediated effector functions in autoimmune and inflammatory diseases. International Immunology, 2017, 29, 491-498.	4.0	204
3	Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2–dependent prostaglandin E2 in human dendritic cells. Blood, 2013, 122, 1419-1427.	1.4	149
4	Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. Journal of Allergy and Clinical Immunology, 2011, 127, 823-830.e7.	2.9	135
5	High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4109-4113.	7.1	110
6	The Prevalence of Proteolytic Antibodies against Factor VIII in Hemophilia A. New England Journal of Medicine, 2002, 346, 662-667.	27.0	107
7	Pooled Normal Human Polyspecific IgM Contains Neutralizing Anti-Idiotypes to IgG Autoantibodies of Autoimmune Patients and Protects From Experimental Autoimmune Disease. Blood, 1997, 90, 4004-4013.	1.4	95
8	Intravenous immunoglobulin as clinical immune-modulating therapy. Cmaj, 2015, 187, 257-264.	2.0	74
9	Shortage of human intravenous immunoglobulinâ€"reasons and possible solutions. Nature Clinical Practice Neurology, 2007, 3, 120-121.	2.5	71
10	IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist. Nature Reviews Immunology, 2014, 14, 349-349.	22.7	68
11	Immunomodulation by Intravenous Immunoglobulin: Role of Regulatory T Cells. Journal of Clinical Immunology, 2010, 30, 4-8.	3.8	63
12	Natural Antibodies: from First-Line Defense Against Pathogens to Perpetual Immune Homeostasis. Clinical Reviews in Allergy and Immunology, 2020, 58, 213-228.	6.5	60
13	Intravenous Gammaglobulin Inhibits Encephalitogenic Potential of Pathogenic T Cells and Interferes with their Trafficking to the Central Nervous System, Implicating Sphingosine-1 Phosphate Receptor 1–Mammalian Target of Rapamycin Axis. Journal of Immunology, 2013, 190, 4535-4541.	0.8	56
14	Comparison of different IVIg preparations on IL-17 production by human Th17 cells. Autoimmunity Reviews, 2011, 10, 809-810.	5.8	55
15	Intravenous Immunoglobulin Expands Regulatory T Cells in Autoimmune Rheumatic Disease. Journal of Rheumatology, 2012, 39, 450-451.	2.0	48
16	Viscum album Exerts Anti-Inflammatory Effect by Selectively Inhibiting Cytokine-Induced Expression of Cyclooxygenase-2. PLoS ONE, 2011, 6, e26312.	2.5	46
17	Catalytic IgG from Patients with Hemophilia A Inactivate Therapeutic Factor VIII. Journal of Immunology, 2006, 177, 1355-1363.	0.8	45
18	Antiangiogenic properties of viscum album extracts are associated with endothelial cytotoxicity. Anticancer Research, 2009, 29, 2945-50.	1.1	40

#	Article	IF	CITATIONS
19	Regulatory T cells induce activation rather than suppression of human basophils. Science Immunology, 2018, 3, .	11.9	38
20	Induction of maturation and activation of human dendritic cells: A mechanism underlying the beneficial effect of Viscum albumas complimentary therapy in cancer. BMC Cancer, 2008, 8, 161.	2.6	37
21	Intravenous immunoglobulin induces IL-4 in human basophils by signaling through surface-bound IgE. Journal of Allergy and Clinical Immunology, 2019, 144, 524-535.e8.	2.9	36
22	Circulating Normal IgG as Stimulator of Regulatory T Cells: Lessons from Intravenous Immunoglobulin. Trends in Immunology, 2017, 38, 789-792.	6.8	35
23	Autoantibodies with enzymatic properties in human autoimmune diseases. Journal of Autoimmunity, 2011, 37, 144-150.	6.5	34
24	Intravenous immunoglobulin-mediated expansion of regulatory T cells in autoimmune patients is associated with increased prostaglandin E2 levels in the circulation. Cellular and Molecular Immunology, 2015, 12, 650-652.	10.5	33
25	Molecular and immunological biomarkers to predict IVIg response. Trends in Molecular Medicine, 2015, 21, 145-147.	6.7	31
26	Basophils and Nephritis in Lupus. New England Journal of Medicine, 2010, 363, 1080-1082.	27.0	27
27	Passive Serum Therapy to Immunomodulation by IVIG: A Fascinating Journey of Antibodies. Journal of Immunology, 2018, 200, 1957-1963.	0.8	26
28	Tackling Difficult Staphylococcus aureus Infections: Antibodies Show the Way. Cell Host and Microbe, 2016, 20, 555-557.	11.0	25
29	Monomeric Immunoglobulin A from Plasma Inhibits Human Th17 Responses In Vitro Independent of FcαRI and DC-SIGN. Frontiers in Immunology, 2017, 8, 275.	4.8	25
30	Antibody-mediated catalysis: Induction and therapeutic relevance. Autoimmunity Reviews, 2013, 12, 648-652.	5.8	24
31	Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy. Journal of Neuroinflammation, 2017, 14, 58.	7.2	23
32	Intravenous immunoglobulin protects from experimental allergic bronchopulmonary aspergillosis via a sialylationâ€dependent mechanism. European Journal of Immunology, 2019, 49, 195-198.	2.9	23
33	Natural Immunomodulators. Journal of Immunology Research, 2017, 2017, 1-2.	2.2	21
34	Heme oxygenase-1 is dispensable for the anti-inflammatory activity of intravenous immunoglobulin. Scientific Reports, 2016, 6, 19592.	3.3	19
35	Exploitation of rolling circle amplification for the construction of large phage-display antibody libraries. Journal of Immunological Methods, 2014, 407, 26-34.	1.4	16
36	Basophils are inept at promoting human Th17 responses. Human Immunology, 2015, 76, 176-180.	2.4	11

#	Article	IF	CITATIONS
37	Kill â€~Em All: Efgartigimod Immunotherapy for Autoimmune Diseases. Trends in Pharmacological Sciences, 2018, 39, 919-922.	8.7	11
38	GM-CSF along with IL-4 but not alone is indispensable for the differentiation of human dendritic cells from monocytes. Journal of Allergy and Clinical Immunology, 2014, 133, 1500-1502.e1.	2.9	9
39	Catalytic antibodies in patients with systemic lupus erythematosus. European Journal of Rheumatology, 2018, 5, 173-178.	0.6	6
40	Mistletoe: From Basic Research to Clinical Outcomes in Cancer and Other Indications. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-2.	1.2	5
41	Intravenous immunoglobulin suppresses the polarization of both classically and alternatively activated macrophages. Human Vaccines and Immunotherapeutics, 2020, 16, 233-239.	3.3	5
42	Generation of Catalytic Antibodies Is an Intrinsic Property of an Individual's Immune System: A Study on a Large Cohort of Renal Transplant Patients. Journal of Immunology, 2016, 196, 4075-4081.	0.8	3